Amgen's BLA761298 for PAVBLU Receives AP Status from FDA
The FDA has granted application BLA761298 for PAVBLU an Approval Pending (AP) status.
Therapeutic Area
Therapeutic area intelligence for VEGF Inhibitor with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.